AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MAYNE PHARMA GROUP LTD

7.040

-0.010-0.14%

Volume:570.06K

Turnover:4.02M

Market Cap:571.97M

PE:-4.30

High:7.070

Open:7.070

Low:7.030

Close:7.050

Loading ...

Overview Company News Filings

Mayne Pharma H1 Revenue AUD 94.3 Million

THOMSON REUTERS

Mayne Pharma H1 Gross Margin 53%

THOMSON REUTERS

Australian Shares Slide Despite Tech Stocks Rally; Mayne Pharma to be Acquired by Cosette in AU$672 Million Deal

MT Newswires Live

Mayne Pharma board backs $672 million takeover bid from Cosette Pharma

Mayne Pharma board backs $672m takeover offer from US giant Cosette

Business News Australia

Mayne Pharma Group Limited (ASX:MYX) Held Back By Insufficient Growth Even After Shares Climb 26%

Simply Wall St.

ASX Market Close: Index inches lower as investors digest Trump’s tariff plans | February 10, 2025

The Market Herald

Mayne Pharma forecasts up to $215m revenue for 1H25 as growth momentum continues

BRIEF-Mayne Pharma Group Says Expects 1H FY25 Revenues To Be A$210 - A$215 Million

Why Ansell, GQG, Mayne Pharma, and Star shares are charging higher today

Mayne Pharma Group Forecasts Growth in Fiscal H1 Revenues, Shares Rise Past 16%

MT Newswires Live

BUZZ-Australia's Mayne Pharma soars 13% on strong first-half earnings forecast

Mayne Pharma Group Ltd Sees 1H FY25 Underlying Ebitda1 of a$30 - a$32 Mln

THOMSON REUTERS

Mayne Pharma Group Ltd - Expects 1H FY25 Revenues to Be a$210 - a$215 Mln

THOMSON REUTERS

Mayne Pharma Group Ltd-Court Approval of Class Action Settlement

THOMSON REUTERS

Discover Alto Metals And 2 More Exciting Penny Stocks On The ASX

Simply Wall St.

BUZZ-Australia's Mayne Pharma plunges; no update on potential buyout interest

BRIEF-Mayne Pharma Group Expects Growth In Underlying EBITDA And Free Cash Flow In Fy25

Mayne Pharma Group - Jul-Oct Revenue a$132.5 Mln

THOMSON REUTERS

Mayne Pharma Group Ltd - Expects Growth in Underlying Ebitda and Free Cash Flow in FY25

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MYX.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MYX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":7.04,"timestamp":1745302320000,"preClose":7.05,"halted":0,"volume":570059,"delay":0,"nameEN":"MAYNE PHARMA GROUP LTD","floatShares":66962087,"shares":81245827,"eps":-1.638289,"marketStatus":"Closed","change":-0.01,"latestTime":"04-22 16:12:00 AEST","open":7.07,"high":7.07,"low":7.03,"amount":4016360,"amplitude":0.005674,"askPrice":7.08,"askSize":2300,"bidPrice":7.02,"bidSize":10488,"shortable":3,"etf":0,"ttmEps":-1.638289,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":7.05,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.860859,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":66962087,"roa":"-0.61%","roe":"-23.75%","lyrEps":-2.188306,"volumeRatio":0.860859,"shares":81245827,"dividePrice":0,"high":7.07,"amplitude":0.005674,"preClose":7.05,"low":7.03,"week52Low":3.74,"pbRate":"1.28","psRate":"1.38","week52High":7.46,"institutionHeld":0,"latestPrice":7.04,"committee":0.640288,"eps":-1.638289,"divideRate":0,"volume":570059,"delay":0,"ttmEps":-1.638289,"open":7.07,"prevYearClose":4.97,"prevWeekClose":7.05,"prevMonthClose":7.23,"prevQuarterClose":7.23,"fiveDayClose":6.98,"twentyDayClose":7.23,"sixtyDayClose":4.47},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514042109","title":"Mayne Pharma H1 Revenue AUD 94.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514042109","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514042109?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:54","pubTimestamp":1740520494,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLX92B737:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2514004217","title":"Mayne Pharma H1 Gross Margin 53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514004217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514004217?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:54","pubTimestamp":1740520494,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLX92B737:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2513239035","title":"Australian Shares Slide Despite Tech Stocks Rally; Mayne Pharma to be Acquired by Cosette in AU$672 Million Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2513239035","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513239035?lang=en_us&edition=fundamental","pubTime":"2025-02-21 14:17","pubTimestamp":1740118679,"startTime":"0","endTime":"0","summary":"Australian shares slid on Friday's close despite gains from Asian markets fuelled by the rise in tech stocks as Chinese tech firm Alibaba Group Holdings' revenue beat estimates.The S&P/ASX 200 Index f","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7002","BK4137","BK7096","DHG.AU","QBE.AU","XAO.AU","LU1303367103.USD","LU2098885051.SGD","LU1815336091.USD","RBA","BK7503","XKO.AU","BK7034","MYX.AU","LU0757428866.USD","XJO.AU","BK7508"],"gpt_icon":0},{"id":"2513378235","title":"Mayne Pharma board backs $672 million takeover bid from Cosette Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2513378235","media":"Small Caps","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513378235?lang=en_us&edition=fundamental","pubTime":"2025-02-21 10:08","pubTimestamp":1740103689,"startTime":"0","endTime":"0","summary":"Mayne Pharma  has received a takeover offer at a price of $7.40 per share from US-based pharmaceutical company Cosette Pharma, valuing the company at $672 million.Cosette has a portfolio of products in women’s health and dermatology and a long history of manufacturing complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories.The US-based firm is backed by healthcare-focused private equity firm Avista Healthcare Partners and funds controlled by private markets investment management firm Hamilton Lane.Mayne Pharma chief executive officer Shawn Patrick O’Brien said this was a pivotal moment in Mayne’s journey to improve patient access to life-enhancing medications.“Attracting an offer from a strategic buyer who is active in the US dermatology and women’s health markets, such as Cosette, reflects the excellent work our teams have been doing to strengthen our company over the last year and more,” chair Frank Condella added.The Mayne Pharma board has ","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Mayne-Pharma-ASX-MYX-Cosette-Pharmaceuticals-takeover-bid.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Mayne-Pharma-ASX-MYX-Cosette-Pharmaceuticals-takeover-bid.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/mayne-pharma-board-backs-takeover-bid-cosette/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2513710233","title":"Mayne Pharma board backs $672m takeover offer from US giant Cosette","url":"https://stock-news.laohu8.com/highlight/detail?id=2513710233","media":"Business News Australia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513710233?lang=en_us&edition=fundamental","pubTime":"2025-02-21 00:00","pubTimestamp":1740067200,"startTime":"0","endTime":"0","summary":"The board of Adelaide-based Mayne Pharma (ASX: MYX) has thrown its ...","market":null,"thumbnail":"https://assets.cdn.thewebconsole.com/S3WEB6082/a_images/67b7c14486236.jpg?v=2&m=37caf18f1cfc79cb642c7453e89f30a7&lqip(10)","type":0,"news_type":0,"thumbnails":["https://assets.cdn.thewebconsole.com/S3WEB6082/a_images/67b7c14486236.jpg?v=2&m=37caf18f1cfc79cb642c7453e89f30a7&lqip(10)"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businessnewsaustralia.com/articles/mayne-pharma-board-backs--672m-takeover-offer-from-us-giant-cosette.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"businessau_stock","symbols":["BK7096","BK7508","MYX.AU"],"gpt_icon":0},{"id":"2511156145","title":"Mayne Pharma Group Limited (ASX:MYX) Held Back By Insufficient Growth Even After Shares Climb 26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511156145","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511156145?lang=en_us&edition=fundamental","pubTime":"2025-02-13 09:33","pubTimestamp":1739410405,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group Limited ( ASX:MYX ) shareholders would be excited to see that the share price has had a great month...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-myx/mayne-pharma-group-shares/news/mayne-pharma-group-limited-asxmyx-held-back-by-insufficient","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2510881995","title":"ASX Market Close: Index inches lower as investors digest Trump’s tariff plans | February 10, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2510881995","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510881995?lang=en_us&edition=fundamental","pubTime":"2025-02-10 14:28","pubTimestamp":1739168880,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.34% at 8,482 points.Investment manager Franklin Templeton says President Trump’s latest trade tariffs threat could be a “strategic negotiating tool or the beginning of a prolonged trade war”. In a client note the company raised the prospect the move would escalate tensions with key US trade partners and heighten the risk of a full-scale trade war.Staples was the best performing sector, up 0.5%, followed by Utilities, up 0.45%. IT was the biggest loser, down 1.4%, followed by Telecommunication, down 1.1%, and Materials, down 0.7%.BlueScope Steel  closed up 1.8% on revelations it will emerge a winner if US President Donald Trump imposes 25% tariffs on all imports of steel and aluminium into the US. BlueScope is one of the biggest steelmakers in the US.Star Entertainment  closed up 13.6% after the casino operator confirmed it hadreceived bids to buy out its stake in Brisbane’s Queen’s Wharf development. Meanwhile, corporate regulatorASIC’s case against former Star","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-index-inches-lower-as-investors-digest-trumps-tariff-plans-february-10-2025-2025-02-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["MYX.AU","BK7078","BK7129","BK7508","SGR.AU","BK7002","BK7016","CAR.AU","POL.AU","BK7503","BSL.AU","BK7104","BK7096","WTC.AU"],"gpt_icon":0},{"id":"2510000363","title":"Mayne Pharma forecasts up to $215m revenue for 1H25 as growth momentum continues","url":"https://stock-news.laohu8.com/highlight/detail?id=2510000363","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510000363?lang=en_us&edition=fundamental","pubTime":"2025-02-10 09:48","pubTimestamp":1739152098,"startTime":"0","endTime":"0","summary":"Mayne Pharma  has reported a forecast revenue of between $210 million and $215m for the first half of the 2025 financial year, reflecting growth of approximately 14% on the previous corresponding period .The company is also expecting to report underlying EBITDA of between $30m and $32m, representing an increase of almost 300% on the pcp.The underlying EBITDA will be driven by continued growth across Mayne’s Women’s Health portfolio, with increased operating leverage and improved margins in its Dermatology product sales.“We have experienced solid trading conditions in the first half as we execute against our corporate strategies, with robust revenue growth recorded, particularly within our Women’s Health segment,” he said.“[We] believe our portfolio of branded medicines within Women’s Health and Dermatology, coupled with the leverage we can generate through our existing infrastructure and efficiencies, will deliver improvements in our financial and operating metrics.”","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Mayne-Pharma-ASX-MYX-December-2024-half-yearly-market-update.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Mayne-Pharma-ASX-MYX-December-2024-half-yearly-market-update.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/mayne-pharma-forecasts-revenue-1h25-growth-momentum-continues/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2510107286","title":"BRIEF-Mayne Pharma Group Says Expects 1H FY25 Revenues To Be A$210 - A$215 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2510107286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510107286?lang=en_us&edition=fundamental","pubTime":"2025-02-10 09:29","pubTimestamp":1739150986,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Group Says Expects 1H FY25 Revenues To Be A$210 - A$215 MillionFeb 10  - Mayne Pharma Group Ltd MYX.AX:EXPECTS 1H FY25 REVENUES TO BE A$210 - A$215 MILLIONSEES 1H FY25 UNDERLYING EBITDA1 OF A$30 - A$32 MILLIONFurther company coverage: MYX.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3P002U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU"],"gpt_icon":0},{"id":"2510562077","title":"Why Ansell, GQG, Mayne Pharma, and Star shares are charging higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2510562077","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510562077?lang=en_us&edition=fundamental","pubTime":"2025-02-10 09:13","pubTimestamp":1739150016,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) is having a underwhelming start to the week. In afternoon trade, the benchmark index is down 0.3% to 8,488.7 points. Four ASX shares that are not letting that hold the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/10/why-ansell-gqg-mayne-pharma-and-star-shares-are-charging-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SGR.AU","ANN.AU","EBIT","BK7096","BK7126","BK4585","MYX.AU","GQG.AU","BK7078","BK7062","BK7508","BK7501","BK4588","DBC","XJO.AU"],"gpt_icon":1},{"id":"2510076240","title":"Mayne Pharma Group Forecasts Growth in Fiscal H1 Revenues, Shares Rise Past 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510076240","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510076240?lang=en_us&edition=fundamental","pubTime":"2025-02-10 08:18","pubTimestamp":1739146727,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  said it forecasts growth in its revenue for the fiscal first half ended Dec. 31, 2024, according to a Monday Australian bourse filing.The firm now expects H1 revenue to be AU$210 million to AU$215 million, reflecting a 12% to 14% rise in the same half-year period the previous year, the filing said.It also expects to report underlying earnings before interest, taxes, depreciation, and amortization during the period of AU$30 million to AU$32 million, representing an increase of 275% to 300% on the prior year period, driven by continued growth across the women's health portfolio, the filing said.Its cash and marketable securities came in at AU$124.9 million as of Dec. 31, 2024, a decline of AU$4.6 million compared to the balance as of Oct. 31, 2024.The firm's shares rose past 16% in early trading on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYX.AU"],"gpt_icon":0},{"id":"2510073040","title":"BUZZ-Australia's Mayne Pharma soars 13% on strong first-half earnings forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2510073040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510073040?lang=en_us&edition=fundamental","pubTime":"2025-02-10 07:43","pubTimestamp":1739144626,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mayne Pharma soars 13% on strong first-half earnings forecast** Shares of Mayne Pharma Group MYX.AX soar 13.3% to A$5.30, their highest level since December 3, 2024** Stock heads for a fourth consecutive session of gains, among top gainers in the ASX All Ordinaries index .AORD** Speciality pharmaceutical firm says it expects 1H25 underlying EBITDA between A$30 million  and A$32 million, up to four-fold jump from last year's A$8 million** Revenue forecast between A$210 million and A$215 million, up to 14% growth** Co expects to see continued growth in 2H25** More than 112,000 shares change hands, vs the 30-day average of about 95,000 shares** MYX up 6.8% this year, including day's moves  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250209:nL4N3P004J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU"],"gpt_icon":0},{"id":"2510022774","title":"Mayne Pharma Group Ltd Sees 1H FY25 Underlying Ebitda1 of a$30 - a$32 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2510022774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510022774?lang=en_us&edition=fundamental","pubTime":"2025-02-10 05:32","pubTimestamp":1739136721,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250209:nFWN3P002U:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2510022772","title":"Mayne Pharma Group Ltd - Expects 1H FY25 Revenues to Be a$210 - a$215 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2510022772","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510022772?lang=en_us&edition=fundamental","pubTime":"2025-02-10 05:32","pubTimestamp":1739136721,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250209:nFWN3P002U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2492169305","title":"Mayne Pharma Group Ltd-Court Approval of Class Action Settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492169305","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492169305?lang=en_us&edition=fundamental","pubTime":"2024-12-19 07:49","pubTimestamp":1734565794,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUE7RD2G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0},{"id":"2486067898","title":"Discover Alto Metals And 2 More Exciting Penny Stocks On The ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2486067898","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486067898?lang=en_us&edition=fundamental","pubTime":"2024-11-26 07:05","pubTimestamp":1732575908,"startTime":"0","endTime":"0","summary":"The Australian market is poised for a modest rise, buoyed by positive developments on Wall Street and reports of a potential Middle East ceasefire. Amidst these broader market movements, investors often look to smaller or newer companies for unique opportunities. Penny stocks, despite their somewhat outdated name, can still offer significant value when backed by strong financials. In this article, we explore three such penny stocks on the ASX that combine balance sheet strength with the potential for notable growth.Click here to see the full list of 1,046 stocks from our ASX Penny Stocks screener.Overview: Alto Metals Limited focuses on the exploration of gold properties in Western Australia and has a market cap of A$66.38 million.Explore historical data to track Alto Metals' performance over time in our past results report.Overview: Mayne Pharma Group Limited is a specialty pharmaceutical company that manufactures and sells branded and generic pharmaceutical products across Australia,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/q0yRN_h1fYD6SjjSkWx5lg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4afa9747177650711578ccd57242a6b7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/q0yRN_h1fYD6SjjSkWx5lg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4afa9747177650711578ccd57242a6b7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/discover-alto-metals-2-more-230508692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7048","BK7502","BK7104","BK4585","XRF.AU","LU1791807156.HKD","BK7055","LU1861220207.SGD","BK4166","LU2360107671.USD","BK7132","GTN.AU","SHA.AU","LU1861217088.USD","XJO.AU","VLS.AU","BK7070","XKO.AU","LBL.AU","NGI.AU","DFS","LU1668664300.SGD","BK7096","XAO.AU","EVO.AU","BK7077","AME.AU","BK7045","EZZ.AU","BK7062","ATP.AU","MYX.AU","BK7508","ANG.AU","HLO.AU","LU0106831901.USD","BK7088","BK4588","BK7131"],"gpt_icon":0},{"id":"2485893884","title":"BUZZ-Australia's Mayne Pharma plunges; no update on potential buyout interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2485893884","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485893884?lang=en_us&edition=fundamental","pubTime":"2024-11-21 11:14","pubTimestamp":1732158872,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mayne Pharma plunges; no update on potential buyout interest** Shares of Australian drugmaker Mayne Pharma MYX.AX fall as much as 7.7% to A$4.11, their lowest since Aug. 23** Co provides no update on potential buyout interest, at its annual general meeting** MYX earlier in the month said Jefferies to assist co in terms of looking for a possible bidder ** Stock posts its biggest intraday pct fall since Nov. 13** Co says total revenue for the July-Oct period came in at A$132.5 mln , lower than the A$137 mln reported in the previous corresponding period** Two analysts covering the stock rate it \"buy\" or higher, their median PT is A$2.0 – LSEG data** Stock had fallen 32.7% this year, as of last close  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nL4N3MS05Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","MYX.AU"],"gpt_icon":0},{"id":"2485910108","title":"BRIEF-Mayne Pharma Group Expects Growth In Underlying EBITDA And Free Cash Flow In Fy25","url":"https://stock-news.laohu8.com/highlight/detail?id=2485910108","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485910108?lang=en_us&edition=fundamental","pubTime":"2024-11-21 09:13","pubTimestamp":1732151635,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Group Expects Growth In Underlying EBITDA And Free Cash Flow In Fy25Nov 21  - Mayne Pharma Group Ltd MYX.AX:EXPECTS GROWTH IN UNDERLYING EBITDA AND FREE CASH FLOW IN FY25FOR JULY-OCT UNDERLYING EBITDA OF A$14.7MJUL-OCT REVENUE A$132.5 MILLIONFurther company coverage: MYX.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MR0WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0},{"id":"2485720841","title":"Mayne Pharma Group - Jul-Oct Revenue a$132.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2485720841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485720841?lang=en_us&edition=fundamental","pubTime":"2024-11-21 06:43","pubTimestamp":1732142625,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MR0WM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2485172288","title":"Mayne Pharma Group Ltd -  Expects Growth in Underlying Ebitda and Free Cash Flow in FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2485172288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485172288?lang=en_us&edition=fundamental","pubTime":"2024-11-21 06:43","pubTimestamp":1732142625,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MR0WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null},{"date":"2024-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708902000000,"name":null,"time":"","dateTimestamp":1708866000000,"actualEps":null},{"date":"2023-08-31","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693440000000,"name":null,"time":"","dateTimestamp":1693404000000,"actualEps":null},{"date":"2023-02-28","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1677538800000,"name":null,"time":"","dateTimestamp":1677502800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}]}}